Solving Vector Yield Challenges in In Vivo CGT Shorts

  1. Why Vector Yield Remains The Biggest Bottleneck In Vivo Gene Therapy 7/23/2026

    During this first segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, define the industry's biggest challenge in balancing biological performance with manufacturability.

  2. Capsid Selection And Tissue Targeting Begin Long Before Manufacturing 7/23/2026

    In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, explain how early biological decisions influence downstream manufacturing success.

  3. When Great Biology Meets Manufacturing Reality 7/23/2026

    During this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, cover why elegant biological designs often struggle during process development and commercial scale up.

  4. Balancing Innovation With Manufacturability When Designing Next Generation Vectors 7/23/2026

    In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, focus on the tradeoffs between biological specificity, clinical precedent, manufacturability, and scalability.

  5. Building Platform Strategies Instead Of One Off Vector Solutions 7/23/2026

    In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, share lessons from their own organizations on balancing innovation with practical development.

  6. The CDMO Perspective On Breaking Down Development Silos In Vivo CGT 7/23/2026

    During this final segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Vishruth Gowda, an associate director on the PD team at Fujifilm Biotechnologie joins Erin Harris to discuss the manufacturing perspective.